STOCK TITAN

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
MacroGenics (MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company's management team will deliver a presentation on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. Interested parties can access the presentation webcast through the Investor Relations section of MacroGenics' website, specifically under the "Events & Presentations" tab. The webcast recording will remain available on the company's website for 30 days after the event.
MacroGenics (MGNX), un'azienda biofarmaceutica specializzata in terapie oncologiche basate su anticorpi, ha annunciato la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Sanità 2025 di Goldman Sachs. Il team di gestione dell'azienda terrà una presentazione martedì 10 giugno 2025 alle 8:00 ET a Miami, FL. Gli interessati potranno seguire la presentazione in webcast attraverso la sezione Relazioni con gli Investitori del sito web di MacroGenics, nella scheda "Eventi e Presentazioni". La registrazione del webcast resterà disponibile sul sito dell'azienda per 30 giorni dopo l'evento.
MacroGenics (MGNX), una empresa biofarmacéutica especializada en terapias contra el cáncer basadas en anticuerpos, ha anunciado su participación en la 46ª Conferencia Global Anual de Salud 2025 de Goldman Sachs. El equipo directivo de la compañía realizará una presentación el martes 10 de junio de 2025 a las 8:00 am ET en Miami, FL. Las personas interesadas podrán acceder a la presentación en webcast a través de la sección de Relaciones con Inversionistas del sitio web de MacroGenics, específicamente en la pestaña "Eventos y Presentaciones". La grabación del webcast estará disponible en el sitio web de la compañía durante 30 días después del evento.
항체 기반 암 치료제를 전문으로 하는 생명공학 제약회사인 MacroGenics(MGNX)는 2025년 골드만삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사 경영진은 2025년 6월 10일 화요일 오전 8시(동부시간) 플로리다 마이애미에서 발표를 진행할 예정입니다. 관심 있는 분들은 MacroGenics 웹사이트의 투자자 관계 섹션 내 "이벤트 및 프레젠테이션" 탭을 통해 발표 웹캐스트에 접속할 수 있습니다. 웹캐스트 녹화는 행사 후 30일 동안 회사 웹사이트에서 시청 가능합니다.
MacroGenics (MGNX), une société biopharmaceutique spécialisée dans les thérapies anticancéreuses à base d'anticorps, a annoncé sa participation à la 46e conférence mondiale annuelle sur la santé de Goldman Sachs en 2025. L'équipe de direction de l'entreprise présentera le mardi 10 juin 2025 à 8h00 ET à Miami, FL. Les personnes intéressées pourront accéder à la diffusion en direct de la présentation via la section Relations Investisseurs du site web de MacroGenics, sous l'onglet « Événements et Présentations ». L'enregistrement de la diffusion restera disponible sur le site de l'entreprise pendant 30 jours après l'événement.
MacroGenics (MGNX), ein biopharmazeutisches Unternehmen, das sich auf antibody-basierte Krebstherapien spezialisiert hat, hat seine Teilnahme an der 46. Goldman Sachs Global Healthcare Conference 2025 angekündigt. Das Management-Team des Unternehmens wird am Dienstag, den 10. Juni 2025, um 8:00 Uhr ET in Miami, FL, eine Präsentation halten. Interessierte können die Präsentation über den Bereich Investor Relations auf der Webseite von MacroGenics unter dem Reiter "Events & Presentations" per Webcast verfolgen. Die Aufzeichnung des Webcasts wird 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
Positive
  • None.
Negative
  • None.

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL.

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcast on its website for 30 days.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.




Contacts:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172
info@macrogenics.com 

Argot Partners
1-212-600-1902
macrogenics@argotpartners.com 

FAQ

When is MacroGenics (MGNX) presenting at the Goldman Sachs Healthcare Conference 2025?

MacroGenics will present at the Goldman Sachs Healthcare Conference on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL.

How can I watch MacroGenics' (MGNX) presentation at the Goldman Sachs Healthcare Conference?

The presentation can be accessed through the 'Events & Presentations' section in MacroGenics' Investor Relations website at http://ir.macrogenics.com/events.cfm

How long will MacroGenics' (MGNX) Goldman Sachs Conference presentation be available online?

MacroGenics will maintain an archived replay of the webcast on its website for 30 days after the presentation.

What is MacroGenics' (MGNX) main business focus?

MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for cancer treatment.
Macrogenics Inc

NASDAQ:MGNX

MGNX Rankings

MGNX Latest News

MGNX Stock Data

93.69M
57.96M
2.26%
93.8%
8.14%
Biotechnology
Pharmaceutical Preparations
Link
United States
Rockville